RxDoctor Payments Data

David Burkett, MD

Cardiovascular Disease · San Antonio, TXNPI 1245258094

Payments from drug & device makers

$31,366in general payments, 2019–2025

Across 312 payments — averaging $100.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$23K
  • Medical Device Business Services, Inc.$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Medtronic$911
  • Merck$574
  • Bayer$388
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$2001%
  • Speaking & faculty fees$17,39355%
  • Travel & lodging$5,81519%
  • Food & beverage$7,95025%
  • Education$80%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,366 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$98,029
Medicare patients
176
Services billed
805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil14$349,495
OpsumitMacitentan12$156,370
EntrestoSacubitril/Valsartan44$50,464
Repatha SureclickEvolocumab23$14,613
EliquisApixaban18$14,203
Repatha SyringeEvolocumab11$6,555
Colchicine82$5,968
Ezetimibe71$2,692
Metoprolol Succinate21$386
Atorvastatin Calcium44$366
Rosuvastatin Calcium29$361
Pravastatin Sodium19$263
Metoprolol Tartrate14$159
Amlodipine Besylate13$110
Losartan Potassium15$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$1,220$156,37012 claims
NovartisEntresto$248$50,46444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →